Literature DB >> 28721494

A Comprehensive Characterization of Parameters Affecting High-Frequency Irreversible Electroporation Lesions.

Tyler Miklovic1, Eduardo L Latouche1, Matthew R DeWitt1, Rafael V Davalos1, Michael B Sano2,3.   

Abstract

Several focal therapies are being investigated clinically to treat tumors in which surgery is contraindicated. Many of these ablation techniques, such as radiofrequency ablation and microwave ablation, rely on thermal damage mechanisms which can put critical nerves or vasculature at risk. Irreversible electroporation (IRE) is a minimally invasive, non-thermal technique to destroy tumors. A series of short electric pulses create nanoscale defects in the cell membrane, eventually leading to cell death. Typical IRE protocols deliver a series of 50-100 µs monopolar pulses. High frequency IRE (H-FIRE) aims to replace these monopolar pulses with integrated bursts of 0.25-10 µs bipolar pulses. Here, we examine ablations created using a broad array of IRE and H-FIRE protocols in a potato tissue phantom model. Our results show that H-FIRE pulses require a higher energy dose to create equivalent lesions to standard IRE treatment protocols. We show that ablations in potato do not increase when more than 40 H-FIRE bursts are delivered. These results show that H-FIRE treatment protocols can be optimized to produce clinically relevant lesions while maintaining the benefits of a non-thermal ablation technique.

Entities:  

Keywords:  Focal ablation; H-FIRE; Non-thermal therapy; Tissue phantom

Mesh:

Year:  2017        PMID: 28721494     DOI: 10.1007/s10439-017-1889-2

Source DB:  PubMed          Journal:  Ann Biomed Eng        ISSN: 0090-6964            Impact factor:   3.934


  8 in total

1.  The Enlargement of Ablation Area by Electrolytic Irreversible Electroporation (E-IRE) Using Pulsed Field with Bias DC Field.

Authors:  Yanpeng Lv; Heqing Liu; Zhikui Feng; Jianhua Zhang; Genyong Chen; Chenguo Yao
Journal:  Ann Biomed Eng       Date:  2022-07-19       Impact factor: 4.219

2.  High-Frequency Irreversible Electroporation for Treatment of Primary Liver Cancer: A Proof-of-Principle Study in Canine Hepatocellular Carcinoma.

Authors:  Brittanie R Partridge; Timothy J O'Brien; Melvin F Lorenzo; Sheryl L Coutermarsh-Ott; Sabrina L Barry; Krystina Stadler; Noelle Muro; Mitchell Meyerhoeffer; Irving C Allen; Rafael V Davalos; Nikolaos G Dervisis
Journal:  J Vasc Interv Radiol       Date:  2020-01-16       Impact factor: 3.464

3.  Real-Time Impedance Monitoring During Electroporation Processes in Vegetal Tissue Using a High-Performance Generator.

Authors:  Borja López-Alonso; Hector Sarnago; Oscar Lucía; Pablo Briz; José Miguel Burdío
Journal:  Sensors (Basel)       Date:  2020-06-02       Impact factor: 3.576

4.  Ablation outcome of irreversible electroporation on potato monitored by impedance spectrum under multi-electrode system.

Authors:  Yajun Zhao; Hongmei Liu; Suyashree P Bhonsle; Yilin Wang; Rafael V Davalos; Chenguo Yao
Journal:  Biomed Eng Online       Date:  2018-09-20       Impact factor: 2.819

Review 5.  Companion animal models of neurological disease.

Authors:  Brittanie Partridge; John H Rossmeisl
Journal:  J Neurosci Methods       Date:  2019-11-13       Impact factor: 2.390

6.  Evaluation of electroporated area using 2,3,5-triphenyltetrazolium chloride in a potato model.

Authors:  Seung Jeong; Hongbae Kim; Junhyung Park; Ki Woo Kim; Sung Bo Sim; Jong Hoon Chung
Journal:  Sci Rep       Date:  2021-10-14       Impact factor: 4.379

7.  Electroporation with Cisplatin against Metastatic Pancreatic Cancer: In Vitro Study on Human Primary Cell Culture.

Authors:  Olga Michel; Julita Kulbacka; Jolanta Saczko; Justyna Mączyńska; Piotr Błasiak; Joanna Rossowska; Adam Rzechonek
Journal:  Biomed Res Int       Date:  2018-03-19       Impact factor: 3.411

Review 8.  Electrotherapies for Glioblastoma.

Authors:  Elise P W Jenkins; Alina Finch; Magda Gerigk; Iasonas F Triantis; Colin Watts; George G Malliaras
Journal:  Adv Sci (Weinh)       Date:  2021-07-22       Impact factor: 16.806

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.